Full Press Release Details
Announces Positive Phase III Psoriasis Interim Data Analysis
PETACH TIKVA, Israel, October 06, 2020
-- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small
molecule drugs that address inflammatory, cancer and liver diseases, today announced that the Independent Data Monitoring Committee
(IDMC) which conducted an interim analysis of the Company's Phase III Comfort trial of Piclidenoson in the treatment
of moderate-to-severe plaque psoriasis, recommended, based on the positive data, to continue the study with the original sample
size and drop one dose group. This means that an optimal dose has been found and that the study can be concluded earlier than
has been originally planned.
separate IDMC for the interim analysis of the Acrobat Rheumatoid Arthritis Phase III study recommended not to continue
this study. The Company plans to undertake a detailed analysis of the data of the RA study and decide on the next steps.
Comfort Phase III psoriasis study is designed to establish Piclidenoson's superiority compared to placebo and non-inferiority
compared to Apremilast (Otezla ) in patients with moderate to severe plaque psoriasis. The randomized, double blind study
is being conducted in Europe, Israel, and Canada. Patients were randomized into four groups: 2 mg Piclidenoson, 3 mg Piclidenoson,
Otezla , and placebo. The study's primary endpoint is the proportion of patients who achieve a PASI score response of
75% (PASI 75) vs. placebo at week 16. The secondary endpoints include non-inferiority to Otezla on weeks 16 and 32.
the interim analysis data continue to be blinded to Can-Fite, and the results have only been available to the IDMC, their recommendation
to continue the Phase III psoriasis study and also to drop one of the dosing groups are highly encouraging. There is a real market
need for an efficacious and safe oral drug for this devastating disease. We thank the members of both of the IDMCs for their diligence
in reviewing our Phase III interim data and for making their recommendations." stated Can-Fite CEO Dr. Pnina Fishman.
majority of costs associated with the Phase III Comfort study were previously paid, and based on the Company's current
cash and its anticipated uses, the Company believes it has sufficient runway to cover the completion of this study.
has been out-licensed for the indication of psoriasis in Canada, South Korea, Spain, Austria, Switzerland, Hong Kong, Macau, Taiwan,
and China. According to iHealthcareAnalyst, the psoriasis therapeutic market is estimated to reach $11.3 billion by 2025.
is a novel, first-in-class, A3 adenosine receptor agonist (A3AR) small molecule, orally bioavailable drug with a favorable therapeutic
index demonstrated in Phase II clinical studies. Piclidenoson is currently under development for the treatment of autoimmune inflammatory
diseases and for the treatment of COVID-19. It is being evaluated in multinational Phase III studies as a first line treatment
to replace methotrexate in the treatment of rheumatoid arthritis, and as a treatment for moderate-to-severe psoriasis.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer, liver, inflammatory disease and COVID-19.
The Company's lead drug candidate, Piclidenoson, is currently in Phase III trials for rheumatoid arthritis and psoriasis. Can-Fite's
liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer,
and successfully achieved its primary endpoint in a Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH).
Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment
for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers
including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile
dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date.
For more information please visit: www.can-fite.com.
press release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among
other things, market risks and uncertainties, its product development efforts, business, financial condition, results of operations,
strategies or prospects. In addition, from time to time, Can-Fite or its representatives have made or may make forward-looking
statements, orally or in writing. Forward-looking statements can be identified by the use of forward-looking words such as "believe,"
"expect," "intend," "plan," "may," "should" or "anticipate"
or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate
strictly to historical or current matters. These forward-looking statements may be included in, but are not limited to, various
filings made by Can-Fite with the U.S. Securities and Exchange Commission, press releases or oral statements made by or with the
approval of one of Can-Fite's authorized executive officers. Forward-looking statements relate to anticipated or expected
events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that
have not yet occurred, these statements are inherently subject to risks and uncertainties that could cause Can-Fite's actual
results to differ materially from any future results expressed or implied by the forward-looking statements. Many factors could
cause Can-Fite's actual activities or results to differ materially from the activities and results anticipated in such forward-looking
statements. Factors that could cause our actual results to differ materially from those expressed or implied in such forward-looking
statements include, but are not limited to: our history of losses and needs for additional capital to fund our operations and
our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working
capital needs; the impact of the recent outbreak of coronavirus; the initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical
trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product
candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance
of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the
implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are
able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our
business without infringing the intellectual property rights of others; competitive companies, technologies and our industry;
statements as to the impact of the political and security situation in Israel on our business; and risks and other risk factors
detailed in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in
an industry sector where securities values are highly volatile and may be influenced by economic and other factors beyond its
control. Can-Fite does not undertake any obligation to publicly update these forward-looking statements, whether as a result of
new information, future events or otherwise.